FindTrial
Sign In

Depression and its relationship with blood levels of acetylcarnitine and coenzyme Q10

Mitochondrial Dysfunction in Depression

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2019/08/020835
Enrollment
60
Registered
2019-08-22
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: F321- Major depressive disorder, singleepisode, moderate Health Condition 2: F323- Major depressive disorder, singleepisode, severe with psychotic features Health Condition 3: F322- Major depressive disorder, singleepisode, severe without psychotic features

Interventions

None listed

Sponsors

Central Institute of Psychiatry
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Inclusion criteria for patients- 1. Patients diagnosed with moderate or severe depressive episode with or without psychotic symptoms according to ICD 10 diagnostic criteria for research (DCR) (WHO, 1993). 2. Patients of either sex between 18-60 years of age. 3. Patients who are drug naive or drug free for minimum 4 weeks from oral antidepressants. 4. Patients giving written informed consent. Inclusion criteria for controls- 1. General health questionnaire (GHQ 12) less than or equal to 3. 2. Controls matching age and sex with the patients. 3. Persons giving written informed consent.

Exclusion criteria

Exclusion criteria: Exclusion criteria for patients- 1. Significant co-morbid conditions like chronic kidney disease, cardiovascular disease, cancer, Type I or II diabetes mellitus. 2. Presence of comorbid neurological or other psychiatric disorders. 3. Patients with comorbid substance dependence except caffeine. 4. Patients not giving written informed consent. Exclusion criteria for controls- 1. General health questionnaire (GHQ 12) score more than 3. 2. Significant co-morbid conditions like chronic kidney disease, cardiovascular disease, cancer, Type I or II diabetes mellitus. 3. Presence of comorbid neurological or other psychiatric disorders. 4. Persons with comorbid substance dependence except caffeine. 5. Persons not giving written informed consent.

Design outcomes

Primary

MeasureTime frame
To assess levels of acetylcarnitine and coenzyme Q-10 in patients with depressive episode and healthy controls. Timepoint: Once cross-sectionally in both cases and controls—

Secondary

MeasureTime frame
To see the correlation between levels of acetylcarnitine and coenzyme Q-10 and symptom severity, severity of somatic symptoms and suicidality in depression. Timepoint: Once cross-sectionally in cases—

Countries

India

Contacts

Public ContactDr Bindu Rathod

Central Institute of Psychiatry

drmanu28@yahoo.in

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026